Article: Glucose intolerance in children with cystic fibrosis

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleGlucose intolerance in children with cystic fibrosis
AuthorsSolomon, MP
Wilson, DC
Corey, M
Kalnins, D
Zielenski, J
Tsui, LC
Pencharz, P
Durie, P
Sweezey, NB1
Issue Date2003
PublisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jpeds
CitationJournal Of Pediatrics, 2003, v. 142 n. 2, p. 128-132 [How to Cite?]
DOI: http://dx.doi.org/10.1067/mpd.2003.5
AbstractObjective: To evaluate the relations among glucose intolerance, genotype, and exocrine pancreatic status in patients with cystic fibrosis (CF). Study design: Data on 335 patients <18 years of age were from the Toronto CF database. A modified oral glucose tolerance test was given to 94 patients 10 to 18 years of age without recognized CF-related diabetes. CF transmembrane conductance regulator mutations and exocrine pancreatic status were determined for all patients. Results: CF-related diabetes was clinically recognized in 9 of 335 (2.7%) patients <18 years of age, all of whom were pancreatic insufficient, and 8 of 9 had severe (classes I through III) mutations on both alleles. The ninth patient had unidentified mutations. Although all patients given the oral glucose tolerance test were asymptomatic and had normal fasting blood glucose, 16 of 94 (17%) had impaired glucose tolerance and 4 of 94 (4.3%) had CF-related diabetes without fasting hyperglycemia. Abnormal glucose tolerance was associated exclusively with severe mutations and exocrine pancreatic insufficiency. Glycosylated hemoglobin (HbA 1C) levels did not correlate with glucose tolerance results. Conclusions: Screening of pancreatic-insufficient, adolescent patients with CF identified more with abnormal oral glucose tolerance than was suspected clinically and is recommended as a routine practice. HbA 1C was not useful in screening for CF-related glucose intolerance.
ISSN0022-3476
2011 Impact Factor: 4.115
2011 SCImago Journal Rankings: 0.209
DOIhttp://dx.doi.org/10.1067/mpd.2003.5
ISI Accession Number IDWOS:000181144400013
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorSolomon, MP
dc.contributor.authorWilson, DC
dc.contributor.authorCorey, M
dc.contributor.authorKalnins, D
dc.contributor.authorZielenski, J
dc.contributor.authorTsui, LC
dc.contributor.authorPencharz, P
dc.contributor.authorDurie, P
dc.contributor.authorSweezey, NB
dc.date.accessioned2007-09-12T03:52:25Z
dc.date.available2007-09-12T03:52:25Z
dc.date.issued2003
dc.description.abstractObjective: To evaluate the relations among glucose intolerance, genotype, and exocrine pancreatic status in patients with cystic fibrosis (CF). Study design: Data on 335 patients <18 years of age were from the Toronto CF database. A modified oral glucose tolerance test was given to 94 patients 10 to 18 years of age without recognized CF-related diabetes. CF transmembrane conductance regulator mutations and exocrine pancreatic status were determined for all patients. Results: CF-related diabetes was clinically recognized in 9 of 335 (2.7%) patients <18 years of age, all of whom were pancreatic insufficient, and 8 of 9 had severe (classes I through III) mutations on both alleles. The ninth patient had unidentified mutations. Although all patients given the oral glucose tolerance test were asymptomatic and had normal fasting blood glucose, 16 of 94 (17%) had impaired glucose tolerance and 4 of 94 (4.3%) had CF-related diabetes without fasting hyperglycemia. Abnormal glucose tolerance was associated exclusively with severe mutations and exocrine pancreatic insufficiency. Glycosylated hemoglobin (HbA 1C) levels did not correlate with glucose tolerance results. Conclusions: Screening of pancreatic-insufficient, adolescent patients with CF identified more with abnormal oral glucose tolerance than was suspected clinically and is recommended as a routine practice. HbA 1C was not useful in screening for CF-related glucose intolerance.
dc.description.natureabstract
dc.identifier.citationJournal Of Pediatrics, 2003, v. 142 n. 2, p. 128-132 [How to Cite?]
DOI: http://dx.doi.org/10.1067/mpd.2003.5
dc.identifier.doihttp://dx.doi.org/10.1067/mpd.2003.5
dc.identifier.epage132
dc.identifier.isiWOS:000181144400013
dc.identifier.issn0022-3476
2011 Impact Factor: 4.115
2011 SCImago Journal Rankings: 0.209
dc.identifier.issue2
dc.identifier.openurl
dc.identifier.pmid12584532
dc.identifier.scopuseid_2-s2.0-0037326312
dc.identifier.spage128
dc.identifier.urihttp://hdl.handle.net/10722/44380
dc.identifier.volume142
dc.languageeng
dc.publisherMosby, Inc. The Journal's web site is located at http://www.elsevier.com/locate/jpeds
dc.publisher.placeUnited States
dc.relation.ispartofJournal of Pediatrics
dc.relation.referencesReferences in Scopus
dc.subject.meshCystic Fibrosis - complications - genetics
dc.subject.meshDiabetes Mellitus - blood - diagnosis - epidemiology - etiology
dc.subject.meshGlucose Intolerance - blood - diagnosis - epidemiology - etiology
dc.subject.meshHemoglobin A, Glycosylated - metabolism
dc.subject.meshMass Screening - methods
dc.titleGlucose intolerance in children with cystic fibrosis
dc.typeArticle
Author Affiliations
  1. Hospital for Sick Children, Toronto